Search - tctmd.com

Displaying 1 - 20 of 46

Sort: Relevancy | Date

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

FDA Panel Declines to Endorse Ventura Interatrial Shunt for HFrEF

News Daily News

FDA Panel Declines to Endorse Ventura Interatrial Shunt for HFrEF

December 05, 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation

News Conference News HFSA 2023

REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation

October 11, 2023

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

News Daily News

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Michael O'Riordan

September 18, 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

FDA: Class I Recall for Left-Sided Impella Pumps Due to TAVI Interaction

News Daily News

FDA: Class I Recall for Left-Sided Impella Pumps Due to TAVI Interaction

July 27, 2023

No-Implant Shunt for HF Looks Safe, Feasible in Early Snapshot

News Conference News TVT 2023

No-Implant Shunt for HF Looks Safe, Feasible in Early Snapshot

Michael O'Riordan

June 12, 2023

CardioMEMS Beats Standard Care in First European RCT: MONITOR-HF

News Conference News ESC Heart Failure 2023

CardioMEMS Beats Standard Care in First European RCT: MONITOR-HF

May 21, 2023

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

News Features

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

April 10, 2023

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

News Conference News THT 2023

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

March 22, 2023

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.